Elanco/$ELAN
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Ticker
$ELAN
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
9,225
ISIN
US28414H1032
Website
Elanco Metrics
BasicAdvanced
$7.1B
19.08
$0.75
1.50
-
Price and volume
Market cap
$7.1B
Beta
1.5
52-week high
$16.15
52-week low
$8.02
Average daily volume
5.9M
Financial strength
Current ratio
2.711
Quick ratio
1.219
Long term debt to equity
68.487
Total debt to equity
69.18
Interest coverage (TTM)
1.17%
Profitability
EBITDA (TTM)
862
Gross margin (TTM)
54.89%
Net profit margin (TTM)
8.43%
Operating margin (TTM)
5.53%
Effective tax rate (TTM)
30.41%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
1.14%
Return on equity (TTM)
6.01%
Valuation
Price to earnings (TTM)
19.08
Price to revenue (TTM)
1.597
Price to book
1.12
Price to tangible book (TTM)
-3.97
Price to free cash flow (TTM)
21.234
Free cash flow yield (TTM)
4.71%
Free cash flow per share (TTM)
67.34%
Growth
Revenue change (TTM)
1.42%
Earnings per share change (TTM)
-128.31%
3-year revenue growth (CAGR)
-2.31%
3-year earnings per share growth (CAGR)
-0.84%
What the Analysts think about Elanco
Analyst ratings (Buy, Hold, Sell) for Elanco stock.
Bulls say / Bears say
Elanco's approval of Bovaer positions the company to capitalize on the growing demand for sustainable livestock solutions, potentially tapping into a market worth $1-2 billion. (Investing.com)
The company's robust pipeline includes six potential blockbuster products slated for launch in 2024 and 2025, indicating strong future growth prospects. (Seeking Alpha)
Elanco has made significant progress in paying down debt following its acquisition of Bayer Animal Health in 2020, improving its financial stability. (Seeking Alpha)
The inclusion of a boxed warning on Zenrelia's label may limit its market adoption, as veterinarians and pet owners could be hesitant to use a product with prominent safety concerns. (Investing.com)
Elanco faces intense competition from established players like Zoetis, which could challenge its market share and growth in the animal health industry. (Investing.com)
Recent pipeline setbacks and product delays have dampened investor sentiment, potentially affecting Elanco's ability to aggressively market and promote new offerings. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Elanco Financial Performance
Revenues and expenses
Elanco Earnings Performance
Company profitability
Elanco News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Elanco stock?
Elanco (ELAN) has a market cap of $7.1B as of June 27, 2025.
What is the P/E ratio for Elanco stock?
The price to earnings (P/E) ratio for Elanco (ELAN) stock is 19.08 as of June 27, 2025.
Does Elanco stock pay dividends?
No, Elanco (ELAN) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Elanco dividend payment date?
Elanco (ELAN) stock does not pay dividends to its shareholders.
What is the beta indicator for Elanco?
Elanco (ELAN) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
